Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis - PubMed (original) (raw)
doi: 10.1111/apt.12365. Epub 2013 Jun 3.
Affiliations
- PMID: 23725320
- DOI: 10.1111/apt.12365
Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis
E Varela et al. Aliment Pharmacol Ther. 2013 Jul.
Abstract
Background: Although incrimination of the intestinal microbiota in the pathogenesis of IBD is widely accepted, few data are available about the role of specific bacteria. Potentially, Faecalibacterium prausnitzii, bacteria with anti-inflammatory properties, might be deficient in ulcerative colitis (UC).
Aim: To quantify F. prausnitzii in the faecal microbiota of UC patients in remission and determine its relationship with relapse.
Methods: A cross-sectional study included 116 UC patients in remission, 29 first-degree relatives and 31 healthy controls. A subset of eighteen patients, recruited during the first month of remission, underwent a 1-year follow-up. Total bacteria and F. prausnitzii were measured by quantitative Real Time PCR (qPCR, copies/g). Calprotectin was determined as inflammatory index (μg/g).
Results: We found that F. prausnitzii was reduced in patients (median, IQR: 1.4 × 10⁸ , 5.1 × 10⁷-4.5 × 10⁸) and relatives (1.7 × 10⁸, 9.3 × 10⁷-5.1 × 10⁸) vs. controls (6.5 × 10⁸, 3.7 × 10⁸-1.6 × 10⁹, P < 0.0001). Moreover, low counts of F. prausnitzii were associated with less than 12 months of remission (8.0 × 10⁷, 2.0 × 10⁷-3.5 × 10⁸ vs. 2.1 × 10⁸, 1.0 × 10⁸-7.9 × 10⁸, P < 0.001) and more than 1 relapse/year (8.0 × 10⁷, 3.2 × 10⁷-3.8 × 10⁸ vs. 1.9 × 10⁸, 6.8 × 10⁷-6.0 × 10⁸, P < 0.01). When patients were followed up, F. prausnitzii increased steadily until reaching similar levels to those of controls if remission persisted (2.9 × 10⁸, 9.3 × 10⁶-1.2 × 10⁹; calprotectin: 76, 19-212), whereas it remained low if patients relapsed (2.2 × 10⁸, 1.4 × 10⁶-3.3 × 10⁸; calprotectin: 1760, 844-3662 P < 0.05 vs. controls).
Conclusions: Defective gut colonisation by F. prausnitzii occurred in UC patients during remission and in their unaffected relatives. The recovery of the F. prausnitzii population after relapse is associated with maintenance of clinical remission.
© 2013 John Wiley & Sons Ltd.
Comment in
- Commentary: is Faecalibacterium prausnitzii a potential treatment for maintaining remission in ulcerative colitis?
Siaw YH, Hart A. Siaw YH, et al. Aliment Pharmacol Ther. 2013 Sep;38(5):551. doi: 10.1111/apt.12404. Aliment Pharmacol Ther. 2013. PMID: 23937459 No abstract available.
Similar articles
- Commentary: is Faecalibacterium prausnitzii a potential treatment for maintaining remission in ulcerative colitis?
Siaw YH, Hart A. Siaw YH, et al. Aliment Pharmacol Ther. 2013 Sep;38(5):551. doi: 10.1111/apt.12404. Aliment Pharmacol Ther. 2013. PMID: 23937459 No abstract available. - Low counts of Faecalibacterium prausnitzii in colitis microbiota.
Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, Cosnes J, Corthier G, Marteau P, Doré J. Sokol H, et al. Inflamm Bowel Dis. 2009 Aug;15(8):1183-9. doi: 10.1002/ibd.20903. Inflamm Bowel Dis. 2009. PMID: 19235886 - Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish Irritable Bowel Syndrome and Inflammatory Bowel Disease phenotypes.
Lopez-Siles M, Martinez-Medina M, Busquets D, Sabat-Mir M, Duncan SH, Flint HJ, Aldeguer X, Garcia-Gil LJ. Lopez-Siles M, et al. Int J Med Microbiol. 2014 May;304(3-4):464-75. doi: 10.1016/j.ijmm.2014.02.009. Epub 2014 Feb 21. Int J Med Microbiol. 2014. PMID: 24713205 - The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis.
Prosberg M, Bendtsen F, Vind I, Petersen AM, Gluud LL. Prosberg M, et al. Scand J Gastroenterol. 2016 Dec;51(12):1407-1415. doi: 10.1080/00365521.2016.1216587. Epub 2016 Aug 9. Scand J Gastroenterol. 2016. PMID: 27687331 Review.
Cited by
- Age-associated effect of kestose on Faecalibacterium prausnitzii and symptoms in the atopic dermatitis infants.
Koga Y, Tokunaga S, Nagano J, Sato F, Konishi K, Tochio T, Murakami Y, Masumoto N, Tezuka JI, Sudo N, Kubo C, Shibata R. Koga Y, et al. Pediatr Res. 2016 Dec;80(6):844-851. doi: 10.1038/pr.2016.167. Epub 2016 Aug 16. Pediatr Res. 2016. PMID: 27537603 Free PMC article. Clinical Trial. - Inflammation-driven brain and gut barrier dysfunction in stress and mood disorders.
Doney E, Cadoret A, Dion-Albert L, Lebel M, Menard C. Doney E, et al. Eur J Neurosci. 2022 May;55(9-10):2851-2894. doi: 10.1111/ejn.15239. Epub 2021 May 17. Eur J Neurosci. 2022. PMID: 33876886 Free PMC article. Review. - Influence of Proton-Pump Inhibitors on the Luminal Microbiota in the Gastrointestinal Tract.
Tsuda A, Suda W, Morita H, Takanashi K, Takagi A, Koga Y, Hattori M. Tsuda A, et al. Clin Transl Gastroenterol. 2015 Jun 11;6(6):e89. doi: 10.1038/ctg.2015.20. Clin Transl Gastroenterol. 2015. PMID: 26065717 Free PMC article. - Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease.
Aldars-García L, Chaparro M, Gisbert JP. Aldars-García L, et al. Microorganisms. 2021 Apr 30;9(5):977. doi: 10.3390/microorganisms9050977. Microorganisms. 2021. PMID: 33946482 Free PMC article. Review. - An Integrative Multiomics Approach to Characterize Prebiotic Inulin Effects on Faecalibacterium prausnitzii.
Park JH, Song WS, Lee J, Jo SH, Lee JS, Jeon HJ, Kwon JE, Kim YR, Baek JH, Kim MG, Yang YH, Kim BG, Kim YG. Park JH, et al. Front Bioeng Biotechnol. 2022 Jan 18;10:825399. doi: 10.3389/fbioe.2022.825399. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 35252133 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical